GH Research (GHRS) to Release Earnings on Tuesday

Key Points

• GH Research (GHRS) is set to release its Q2 2025 earnings on September 2nd, with analysts expecting a loss of ($0.22) per share for the quarter.
• The company recently reported ($0.15) EPS, beating estimates by $0.07, but analysts predict an average of ($1 EPS) for both the current and next fiscal years.
• GH Research has seen significant analyst interest, with price targets ranging from $25.00 to $40.00, and received an overall rating of "Moderate Buy" based on consensus projections.

GH Research (NASDAQ:GHRS - Get Free Report) will likely be issuing its Q2 2025 results before the market opens on Tuesday, September 2nd. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties may visit the the company's upcoming Q2 2025 earningresults page for the latest details on the call scheduled for Friday, September 12, 2025 at 12:30 PM ET.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. On average, analysts expect GH Research to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GH Research Trading Down 2.5%

NASDAQ:GHRS traded down $0.34 on Friday, reaching $13.50. 84,476 shares of the stock traded hands, compared to its average volume of 248,770. The company has a market capitalization of $702.41 million, a price-to-earnings ratio of -18.24 and a beta of 0.97. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50. The company's fifty day simple moving average is $14.01 and its 200 day simple moving average is $12.10.

Analysts Set New Price Targets

A number of brokerages have recently commented on GHRS. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price target for the company. Zacks Research lowered shares of GH Research from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Guggenheim reduced their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, May 9th. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price target on shares of GH Research in a research note on Tuesday, June 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $32.00.

Institutional Trading of GH Research

An institutional investor recently bought a new position in GH Research stock. JPMorgan Chase & Co. bought a new stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,500 shares of the company's stock, valued at approximately $79,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).